Premium
Somatic mutations and germline sequence variants in patients with familial colorectal cancer
Author(s) -
Gylfe Alexandra E.,
Sirkiä Johanna,
Ahlsten Manuel,
Järvinen Heikki,
Mecklin JukkaPekka,
Karhu Auli,
Aaltonen Lauri A.
Publication year - 2010
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.25529
Subject(s) - nonsynonymous substitution , germline , genetics , germline mutation , biology , missense mutation , gene , colorectal cancer , mutation , cancer , genome
Abstract It is estimated that up to 35% of colorectal cancers (CRC) can be explained by hereditary factors. However, genes predisposing to highly penetrant CRC syndromes account for only a small fraction of all cases. Thus, most CRCs still remain molecularly unexplained. A recent systematic sequencing study on well‐annotated human protein coding genes identified 280 somatically mutated candidate cancer genes ( CAN genes) in breast and colorectal cancer. It is estimated that 8% of all reported cancer genes show both somatic and germline mutations. Therefore, the identified CAN genes serve as a distinct set of candidates for being involved in hereditary susceptibility. The aim of this study was to evaluate the role of colorectal CAN genes in familial CRC. Samples from 45 familial CRCs without known cancer predisposing mutations were screened for somatic and germline variants in 15 top‐ranked CAN genes. Six of the genes were found to be somatically mutated in our tumor series. We identified 22 nonsynonymous somatic mutations of which the majority was of missense type. In germline, three novel nonsynonymous variants were identified in the following genes: CSMD3 , EPHB6 and C10orf137 , and none of the variants were present in 890 population‐matched healthy controls. It is possible that the identified germline variants modulate predisposition to CRC. Functional validation and larger sample sets, however, will be required to clarify the role of the identified germline variants in CRC susceptibility.